^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TNFRSF12A (TNF Receptor Superfamily Member 12A)

    i
    Other names: TNFRSF12A, TNF Receptor Superfamily Member 12A, FN14, TweakR, CD266, Fibroblast Growth Factor-Inducible Immediate-Early Response Protein 14, Tumor Necrosis Factor Receptor Superfamily Member 12A, FGF-Inducible 14, Tweak-Receptor, Tumor Necrosis Factor Receptor Superfamily, Member 12A, Type I Transmembrane Protein Fn14, CD266 Antigen, TWEAKR
    Associations

    News

    Trials
    14d
    Time‑resolved multi-omic analysis of paclitaxel exposure in human iPSC‑derived sensory neurons unveils mechanisms of chemotherapy‑induced peripheral neuropathy. (PubMed, Cell Death Dis)
    In summary, paclitaxel induces transcriptomic and proteomic signatures of the neuronal stress response, neuroinflammation, nociception, and disturbed metabolism. These may explain, in part, the clinical phenotype of sensory loss, hypersensitivity, and neuropathic pain frequently observed in patients suffering from CIPN, but constitute pharmacologically addressable targets.
    Journal
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • BCL2L11 (BCL2 Like 11) • CASP3 (Caspase 3) • CYSLTR2 (Cysteinyl Leukotriene Receptor 2) • IL1R1 (Interleukin 1 receptor, type I) • ARID5A (AT-Rich Interaction Domain 5A) • ATF3 (Activating Transcription Factor 3) • BBC3 (BCL2 Binding Component 3) • CAMK2A (Calcium/Calmodulin Dependent Protein Kinase II Alpha) • DUSP1 (Dual Specificity Phosphatase 1) • HMGCS1 (3-Hydroxy-3-Methylglutaryl-CoA Synthase 1) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
    |
    paclitaxel
    1m
    CiFGNA: Comprehensive information-based functional gene network analysis. (PubMed, Stat Methods Med Res)
    Key findings revealed gene networks centered on CD52, EPCAM, and TNFRSF12A as markers of drug-response phenotypes, suggesting that targeting resistance-related molecular interactions (e.g. CD52 and EPCAM) or enhancing sensitivity-associated markers such as TNFRSF12A may improve chemotherapy efficacy. Overall, CiFGNA offers a powerful, generalizable tool for interpreting complex gene networks and advancing systems-level understanding of disease mechanisms.
    Journal
    |
    EPCAM (Epithelial cell adhesion molecule) • CD52 (CD52 Molecule) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
    3ms
    METTL14 Regulates the Expression of Genes Related to Interferon, Interleukin and MHC Class I in Nasopharyngeal Carcinoma Cells. (PubMed, Cancer Med)
    These findings demonstrate, for the first time, that METTL14 modulates the expression of genes related to TNF, IFN, IL, and MHC class I in NPC, proposing a novel role for METTL14 in linking inflammation with cancer, a function that has not been fully elucidated.
    Journal
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • IL7R (Interleukin 7 Receptor) • TNFRSF9 (TNF Receptor Superfamily Member 9) • HLA-B (Major Histocompatibility Complex, Class I, B) • IL32 (Interleukin 32) • CD40LG (CD40 ligand) • IFI16 (Interferon Gamma Inducible Protein 16) • IL1B (Interleukin 1, beta) • IL7 (Interleukin 7) • PSMA2 (Proteasome 20S Subunit Alpha 2) • PSMC6 (Proteasome 26S Subunit, ATPase 6) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • HLA-C (Major Histocompatibility Complex, Class I, C) • METTL14 (Methyltransferase 14) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
    3ms
    Over-Expression of TNFRSF12A Promotes Immune Suppression and Facilitates Angiogenesis in Triple-Negative Breast Cancer. (PubMed, Biology (Basel))
    Concurrently, we reveal a TNFRSF12A-mediated chemosensitizing effect towards docetaxel. Therefore, these results are crucial for improving the targeting of TNFRSF12A and developing precise combination treatment regimens to improve outcomes for patients with TNBC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
    |
    HER-2 expression
    |
    docetaxel
    3ms
    Development of a PANoptosis-Related Pathomics Prognostic Model in Ovarian Cancer: A Multi-Omics Study. (PubMed, J Cell Mol Med)
    The PANPM, manifesting distinct advantages for clinical application by accurately extracting pathological features, performed excellently in validation and the high-risk group indicated a poor prognosis. Additionally, STAT4+ T cells may inhibit OC, by activating the PANoptosis of epithelial cells through TNFSF12-TNFRSF12A and TNF-TNFRSF1A, which sheds light on potential therapeutic interventions involving STAT4+ T cells.
    Journal
    |
    TNFRSF1A (TNF Receptor Superfamily Member 1A) • STAT4 (Signal Transducer And Activator Of Transcription 4) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
    4ms
    Neoadjuvant chemotherapy modulates mast cell phenotypes and immune infiltration in high-grade serous carcinoma. (PubMed, Gynecol Oncol)
    Successful NACT was associated with a reduction in CD52 + KIT+ mast cells and an increase in the JUN+/TNFRSF12A+ subpopulation. The increased infiltration of KIT-expressing mast cells may serve as a prognostic biomarker for HGSC following NACT and represent a potential novel therapeutic target to enhance NACT efficacy.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD8 (cluster of differentiation 8) • CD52 (CD52 Molecule) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
    |
    KIT expression
    7ms
    Tumor Necrosis Factor Receptor Superfamily Member 12A Enhances Retinal Ganglion Cell Survival and Promotes Axon Regeneration. (PubMed, FASEB J)
    Transcriptomic analysis of Fn14-overexpressing retinas in the ONC model further revealed significant downregulation of suppressor of cytokine signaling 3 (Socs3), a finding validated in both injury models. Our study highlights Fn14 as a key regulator of optic nerve injury, capable of enhancing RGC survival and axon regeneration.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • RBPMS (RNA-binding protein with multiple splicing) • SOCS3 (Suppressor Of Cytokine Signaling 3) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
    8ms
    Potential role of TNFRSF12A in linking glioblastoma and alzheimer's disease via shared tumour suppressor pathways. (PubMed, Sci Rep)
    This study identifies TNFRSF12A as a cross-disease candidate gene in GBM and AD, based on transcriptomic convergence and partial functional validation. Our findings suggest that TSGs may contribute to shared molecular programs in neurodegeneration and cancer, and warrant further mechanistic investigation.
    Journal
    |
    APP (Amyloid Beta Precursor Protein) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
    9ms
    TNFRSF12A expression in stomach adenocarcinoma and its preliminary role in predicting immunotherapy response. (PubMed, Front Immunol)
    The present study not only reveals the potential of TNFRSF12A as a therapeutic target for STAD, but also explores its great potential in STAD immunotherapy. This finding opens up a new way of thinking for the personalized treatment of STAD.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
    9ms
    Identification and verification of a polyamine metabolism-related gene signature for predicting prognosis and immune infiltration in osteosarcoma. (PubMed, J Orthop Surg Res)
    The identification of FAM162A, SIGMAR1, SQLE, PYCR1, DDI1, PAQR6, GRIA1, and TNFRSF12A as prognostic genes associated with PMRGs in OS provides valuable references for prognostic assessment and personalized treatment in patients with OS.
    Journal • Gene Signature
    |
    PYCR1 (Pyrroline-5-Carboxylate Reductase 1) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
    12ms
    Disulfidptosis related immune genes drive prognostic model development and tumor microenvironment characterization in bladder urothelial carcinoma. (PubMed, Sci Rep)
    We constructed a novel risk score model that combines disulfidptosis and immune genes, demonstrating good prognostic prediction performance. We discovered and verified that the TNFRSF12A gene is an oncogene in BLCA, which may help provide personalized guidance for individualized treatment and immunotherapy selection for BLCA patients to a certain extent.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • TNFRSF12A (TNF Receptor Superfamily Member 12A)
    12ms
    Bioinformatic analysis of molecular expression patterns during the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). (PubMed, Sci Rep)
    Furthermore, our analysis identified CYP7A1 and TNFRSF12A as significantly associated with the prognosis of MASLD progressing to HCC. These findings contribute to the understanding of gene expression dynamics in MASLD and may pave the way for the development of effective prognostic tools and targeted therapies in the realm of liver disease.
    Journal
    |
    TNFRSF12A (TNF Receptor Superfamily Member 12A)